Advertisement

ASCO 2022: Dostarlimab-gxly in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer
Posted: 06/27/2022 | By: Sarah Campen, PharmD

Question 1 of 5

Which statement regarding rectal cancer is FALSE?

Choose 1

A
Approximately 5% to 10% of rectal adenocarcinomas are mismatch repair–deficient
B
Standard treatment of locally advanced rectal cancer is associated with marked complications and toxic effects, including infertility; decreased quality of life; and bowel, urinary, and sexual dysfunction
C
Mismatch repair–deficient rectal carcinoma is highly responsive to standard chemotherapy regimens
D
Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage